Director, Marrow Transplantation, Baylor U. Medical Center, Dallas TX
Oncology
Dr. Edward D. Agura, MD
|
|
Give Review
Dr. Edward D. Agura is an expert in the field of Oncology. He researched medicine at NYU School of Medicine. Edward Agura is a published doctor and has 44 publications published. The lastest was: 'Treatment of T prolymphocytic leukemia with allogeneic bone marrow transplantation.' Edward D. Agura accepts Medicare payments and is listed with Medicare.gov.
Publications
- Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic Cell transplantation.
- Long-term outcome of patients with multiple myeloma after autologous hematopoietic Cell transplantation and nonmyeloablative allografting.
- Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic Syndrome and myeloproliferative disord...
- Progress in the treatment of Acute myeloid leukemia.
- Nonmyeloablative unrelated donor hematopoietic Cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma.
- Acute graft-versus-host disease after liver transplantation: role of withdrawal of immunosuppression in therapeutic management.
- Factors associated with outcomes in allogeneic hematopoietic Cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic Cell tran...
- Graft-vs-host disease as a complication of lung transplantation.
- HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid Leukemia.
- Antiemetic efficacy and pharmacokinetics of intravenous ondansetron infusion during chemotherapy conditioning for bone marrow transplant.
- Seizure in a normal marrow donor: Addison''s Disease unmasked.
- Cyclophosphamide cardiac injury mimicking Acute myocardial infarction.
- Identification and sequence analysis of the promoter for the leukocyte integrin beta-subunit (CD18): a retinoic acid-inducible gene.
- Randomized, double-blind, placebo-controlled trial to evaluate the hematopoietic growth factor PIXY321 after moderate-dose fluorouracil, doxorubicin, and cyclophospham...
- Chronic graft-versus-host disease and other late complications of bone marrow transplantation.
- Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic Cell transplantation following nonmyeloablative conditioning.
- HLA-matched unrelated donor hematopoietic Cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies.
- Treatment for Acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors.
- Modification of the Bu/Cy myeloablative regimen using daily parenteral busulfan: reduced toxicity without the need for pharmacokinetic monitoring.
- Hematopoietic Cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML.
- Treatment of T prolymphocytic Leukemia with allogeneic bone marrow transplantation.
- Factors affecting thymic function after allogeneic hematopoietic stem Cell transplantation.
- Rare occurrence of N-ras point mutations in Philadelphia chromosome positive chronic myeloid Leukemia.
- HLA class I null alleles and new alleles affect unrelated bone marrow donor searches.
- The use of ranitidine in bone marrow transplantation. A review of 223 cases.
- Allogeneic blood Cell transplantation without posttransplant colony-stimulating factors in patients with hematopoietic neoplasm: a phase II study.
- Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic Cell transplantation for advanced hematologic malignancies.
- Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracy...
- Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with Acute myeloid leukemia.
- Nonmyeloablative allogeneic hematopoietic Cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma.
- Allogeneic hematopoietic Cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle Cell lymphoma.
- Effect of up-front daclizumab when combined with steroids for the treatment of Acute graft-versus-host disease: results of a randomized trial.
- Liver transplant-associated Graft-versus-host disease.
- Related and unrelated nonmyeloablative hematopoietic stem Cell transplantation for malignant diseases.
- Relapse risk in patients with malignant diseases given allogeneic hematopoietic Cell transplantation after nonmyeloablative conditioning.
- Five-year follow-up of patients with advanced chronic lymphocytic Leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.
- Non-myeloablative allogeneic haematopoietic Cell transplantation for relapsed diffuse large B-Cell lymphoma: a multicentre experience.
- Twenty years of unrelated donor hematopoietic Cell transplantation for adult recipients facilitated by the National Marrow Donor Program.
- The national marrow donor program 20 years of unrelated donor hematopoietic Cell transplantation.
- Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic Leukemia.
- Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear Cell transplantation after nonmyeloablative conditioning: the effect of po...
- Graft vs host disease following kidney transplantation using an ''0 HLA antigen mismatched'' donor.
- Acute graft versus host disease after liver transplantation: patterns of lymphocyte chimerism.
Schools
New York University
Boston City Hospital
Procedures Preformed
- Bone Marrow Transplant
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Antiphospholipid Syndrome (APS)
- Basal Cell Carcinoma
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
Boston University Medical Center -
NYU School of Medicine
Hospital
-
Baylor University Medical Center -
Medical City Dallas Hospital -
Baylor All Saints Medical Center at Fort Worth
Drug Facts
| NPI NUMBER | 1871531350 | |
| NPPES Provider LastName | AGURA | |
| NPPES Provider FirstName | EDWARD | |
| NPPES Provider ZIPCode | 752462003 | |
| NPPES Provider State | TX | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 786.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 44.0 | |
| Percent Opioid Claims | 5.6 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1871531350 |
| Last Name Of The Provider | AGURA |
| First Name Of The Provider | EDWARD |
| View All |
Similar Doctors
|
|
Dr. Houston E. Holmes III, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Siayareh Rambally, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Micah M. Burch, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cynthia R. Osborne, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Klaus Hollmig, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Laura F. Defina, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Emil T. Kuriakose, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Roy S. Paulson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lalan S. Wilfong, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James B. Brugarolas, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Pavel A. Levin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Subramanian Yegappan, MB |